# David Donabedian, PhD

> David Donabedian, PhD is a Series A investor at KALA BIO backing Neuroscience and Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [KALA BIO](https://shizune.co/investors/profile/kala-pharmaceuticals)
- Location: Boston, United States
- Total investments: 1
- Last investment: Feb 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/david-donabedian-73050a/

David Donabedian, PhD is a Series A investor at KALA BIO in Boston focused on Neuroscience and Biotechnology. David Donabedian is the Co-Founder and Start-up CEO of Solu Therapeutics. He previously worked at DEM Biopharma, Inc. as a Co-Founder, Start-up CEO, Sr. Advisor. David Donabedian attended UNC Kenan-Flagler Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Neuroscience | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Newleos Therapeutics | Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines. | $93.5M | Series A | Feb 13, 2025 |  |

1 of 1 investments shown.

## Co-investors
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 1 deal together
- [DCVC Bio](https://shizune.co/investors/profile/dcvc-bio) — VC Fund, 1 deal together
- [Goldman Sachs Alternatives](https://shizune.co/investors/profile/goldman-sachs-alternatives) — VC Fund, 1 deal together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 1 deal together

## About KALA BIO

VC Fund · Waltham, United States

Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.

5 contacts available at KALA BIO.

| Name | Title | Profile |
| --- | --- | --- |
| Bennett Shapiro | Scientific Advisors | https://shizune.co/investors/profile/dr-bennett-shapiro |
| David Donabedian | Board of Directors | https://shizune.co/investors/profile/david-donabedian |
| David Donabedian, PhD | Board of Directors | https://shizune.co/investors/profile/david-h-donabedian |
| Andrea Franz | Chief Financial Officer | https://shizune.co/investors/profile/andrea-franz |
| Gregory D. Perry | Audit Committee Chairman | https://shizune.co/investors/profile/gregory-d-perry |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does David Donabedian, PhD invest in?

David Donabedian, PhD invests primarily in Neuroscience and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did David Donabedian, PhD last invest?

The most recent investment recorded for David Donabedian, PhD closed in Feb 2025. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co